All News

Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow

#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh

#EULAR2022 Telemedicine: PROs 💻Triage, reduce wait time, direct other specialty referral 💻High agreement w F2F evaluation (79-97%) 💻Saves resources, react quickly to minor flare 💻Better adherence @RheumNow

BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6

#EULAR2022 R Landewe: Anti-Telemedicine 🩺Rheumatology about long-term relationship & communication 🩺"Telemedicine impoverishes visit" by only exchanging information @Rheumnow

#POS0752 #EULAR2022 Is there difference btw childhood- vs adult-onset #lupus?A cohort study of claims database >10,000 pts showed: Children had higher activity & more likely to receive immunosuppressant Some activities persisted Useful to bear in transition clinic @RheumNow https://t.co/KVHZUgAOlV

Inflammation (ESR >20 and cardiovascular risk scores) in AxSpA pts associated with incident hypertension. csDMARD may be associated with HTN NSAID and biologics not associated with incident HTN @RheumNow #EULAR2022 ABST#POS0154 https://t.co/5pYjXrpCec

#PEARLS by EULAR President Prof Iagnocco: 1. Enthesitis can be present in 25% of #SLE patients 2. Erosions can be common and independent of ACPA/RF status 3. Active myositis is indistinguishable from IIM 4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve

#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH

Staggering facts by Prof Vital on #SLE and SkM Sx’s: - 50% of first Sx’s is SkM - SkM Sx are in top 3 concerns for pts - 34% pts w/SkM Sx stopped working median 4 yrs - SkM damage clusters with CVD damage #EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ

📲The great debate on Telemedicine 💻 R. Landewe warns us against "check box medicine" and its consequences on AxSpA overdiagnosis. @RheumNow #EULAR2022 https://t.co/Xwg0aAdHwE

“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs

Ok to taper? In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering. 69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months. Taper group did use more NSAIDs, cDMARDs, steroids @RheumNow #EULAR2022 ABST#OP0261

JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Needs more data but looks promising most w partial response . 5 on #Tofacitinib and 2 w #Baricitinib. ⁦@eular_org⁩ #EULAR2022 POS0014 ⁦@RheumNow⁩ https://t.co/j9IRgT9XJf

Insightful session with H Schulze-Koops: JAKi-Are all promises fulfilled? "JAKi have not shown us sufficient data to prove that they can induce remission or inhibit disease progression" @RheumNow #EULAR2022 https://t.co/SKKAS1ViIU

Dr. Werth shared her evidence based algorithm for managing cutaneous lupus published here: https://t.co/RytrxLdLHK #EULAR2022 @rheumnow https://t.co/wq28btM24U

https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41480

#EULAR2022 @ChristianDejaco: Do we need see our patient at all? Provocative statement asking if some disease states can be evaluated, diagnosed, educated and monitored digitally. "It's already out there!" "Should we leave it to the market" or should rheum take a lead? @RheumNow https://t.co/iMrlKZgtbg

Casado et al. Efficacy of US guided needle fragmentation or lavage for calcific tendonitis refractory subacromial injection. Mean VAS decreased from 7.6±1.5 to 4.5±3.8 at month 4, 82.9% radiologic improvement. No control group! @RheumNow #EULAR2022 OP0289 https://t.co/KarkB7XL8u

EULAR Abstract Archive

Pregnancy data in SpA from 122 pts 40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial dz 7 pts required start of TNFi during 2nd or 3rd trimester 40% post-partum @RheumNow #EULAR2022 ABST#POST0151 https://t.co/cdFRhRuCVH

#EULAR2022 POS0276 Xray & US for CPPD: US: sensitivity in all sites Xray: highly specific, low sensitivity Combo: Best for patients with Negative Xray or Inconclusive US (only one positive site) @Rheumnow @MymaAlbaydaMD @USSONAR_Rh

Topics

All News

Do you get our email newsletter?